Download PDF
Semin Neurol 2007; 27(2): 123-132
DOI: 10.1055/s-2007-971173
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Wilson's Disease

Ronald F. Pfeiffer1
  • 1Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee
Further Information

Publication History

Publication Date:
27 March 2007 (online)

   Permissions and Reprints

ABSTRACT

Wilson's disease is an autosomal-recessive disorder caused by mutation in the ATP7B gene, with resultant impairment of biliary excretion of copper. Subsequent copper accumulation, first in the liver but ultimately in the brain and other tissues, produces protean clinical manifestations that may include hepatic, neurological, psychiatric, ophthalmological, and other derangements. Genetic testing is impractical because of the multitude of mutations that have been identified, so accurate diagnosis relies on judicious use of a battery of laboratory and other diagnostic tests. Lifelong palliative treatment with a growing stable of medications, or with liver transplantation if needed, can successfully ameliorate or prevent the progressive deterioration and eventual death that would otherwise inevitably ensue. This article discusses the epidemiology, genetics, pathophysiology, clinical features, diagnostic testing, and treatment of Wilson's disease.

KEYWORDS

Ceruloplasmin - copper - Wilson's disease - penicillamine - zinc

REFERENCES

  • 1 Walshe J M. History of Wilson's disease: 1912 to 2000.  Mov Disord. 2006;  21 142-147
    CrossrefPubMedGoogle Scholar
  • 2 Wilson S AK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver.  Brain. 1912;  34 295-507
    CrossrefPubMedGoogle Scholar
  • 3 Kayser B. Uber einen Fall von angeborener grünlicher Verfärbung der Kornea.  Klin Monatsbl Augenheilkd. 1902;  40 22-25
    PubMedGoogle Scholar
  • 4 Fleischer B. Zwei weiterer Falle von grünlicher Verfärbung der Kornea.  Klin Monatsbl Augenheilkd. 1903;  41 489-491
    PubMedGoogle Scholar
  • 5 Fleischer B. Uber eine der “Pseudosklerose” nahestehende, bisher unbekannte Krankheit (gekennzeichnet durch tremor, psychische storungen, braunliche Pigmentierung bestimmter gewebe, inbesondere auch der Hornhautperipherie, Lebercirrhose).  Dtsch Z Nervenheilkd. 1912;  44 179-201
    CrossrefPubMedGoogle Scholar
  • 6 Rumpel A. Über das Wesen und die Bedeutung der Leberveränderungen und der Pigmentierunen bei den damit verbundenen Fällen von Psuedosklerose, zugleich ein Beitrag zur Lehre von der Pseudosklerose (Westphal-Strümpell).  Dtsch Z Nervenheilkd. 1913;  49 54-73
    CrossrefPubMedGoogle Scholar
  • 7 Mandelbrote B M, Stanier M W, Thompson R HS, Thurston M N. Studies on copper metabolism in demyelinating diseases of the central nervous system.  Brain. 1948;  71 212-228
    CrossrefPubMedGoogle Scholar
  • 8 Cumings J N. The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration.  Brain. 1948;  71 410-415
    PubMedGoogle Scholar
  • 9 Scheinberg I H, Gitlin D. Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilson's disease).  Science. 1952;  116 484-485
    CrossrefPubMedGoogle Scholar
  • 10 Bearn A G, Kunkel H G. Biochemical abnormalities in Wilson's disease.  J Clin Invest. 1952;  31 616
    PubMedGoogle Scholar
  • 11 Frommer D J. Defective biliary excretion of copper in Wilson's disease.  Gut. 1974;  15 125-129
    PubMedGoogle Scholar
  • 12 Saito T. An assessment of efficiency in potential screening for Wilson's disease.  J Epidemiol Community Health. 1981;  35 274-280
    PubMedGoogle Scholar
  • 13 Scheinberg I H, Sternlieb I. Wilson's Disease. Philadelphia; WB Saunders 1984
    Google Scholar
  • 14 Brewer G J. Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management. Boston; Kluwer Academic Publishers 2001
    Google Scholar
  • 15 Olivarez L, Caggana M, Pass K A, Ferguson P, Brewer G J. Estimate of the frequency of Wilson's disease in the US Caucasian population: a mutation analysis approach.  Ann Hum Genet. 2001;  65 459-463
    CrossrefPubMedGoogle Scholar
  • 16 Bull P C, Thomas G R, Rommens J M, Forbes J R, Cox D W. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene.  Nat Genet. 1993;  5 327-337
    CrossrefPubMedGoogle Scholar
  • 17 Petrukhin K, Fischer S G, Piratsu M et al.. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene.  Nat Genet. 1993;  5 338-343
    CrossrefPubMedGoogle Scholar
  • 18 Yamaguchi Y, Heiny M E, Gitlin J D. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease.  Biochem Biophys Res Commun. 1993;  197 271-277
    CrossrefPubMedGoogle Scholar
  • 19 Petrukhin K, Lutsenko S, Chernov I, Ross B M, Kaplan J H, Gilliam T C. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions.  Hum Mol Genet. 1994;  3 1647-1656
    PubMedGoogle Scholar
  • 20 Cox D W, Prat L, Walshe J M, Heathcote J, Gaffney D. Twenty-four novel mutations in Wilson disease patients of predominantly European ancestry.  Hum Mutat. 2005;  26 280-286
    PubMedGoogle Scholar
  • 21 Loudianos G, Lovicu M, Dessi V et al.. Abnormal mRNA splicing resulting from consensus sequence splicing mutations of ATP7B.  Hum Mutat. 2002;  20 260-266
    CrossrefPubMedGoogle Scholar
  • 22 Gromadzka G, Schmidt H H, Genschel J et al.. p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease.  Mov Disord. 2006;  21 245-248
    CrossrefPubMedGoogle Scholar
  • 23 Vrabelova S, Letocha O, Borsky M, Kozak L. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease.  Mol Genet Metab. 2005;  86 277-285
    CrossrefPubMedGoogle Scholar
  • 24 Gromadzka G, Schmidt H H-J, Genschel J et al.. Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease.  Clin Genet. 2005;  68 524-532
    CrossrefPubMedGoogle Scholar
  • 25 Senzolo M, Loreno M, Fagiuoli S et al.. Different neurological outcome of liver transplantation for Wilson's disease in two homozygotic twins.  Clin Neurol Neurosurg. 2007;  109 71-75
    CrossrefPubMedGoogle Scholar
  • 26 Grubenbecher S, Stüve O, Hefter H, Korth C. Prion protein gene codon 129 modulates clinical course of neurological Wilson disease.  Neuroreport. 2006;  17 549-552
    CrossrefPubMedGoogle Scholar
  • 27 Merle U, Stremmel W, Gessner R. Influence of homozygosity for methionine at codon 129 of the human prion gene on the onset of neurological and hepatic symptoms in Wilson disease.  Arch Neurol. 2006;  63 982-985
    CrossrefPubMedGoogle Scholar
  • 28 Sechi G, Antonio Cocco G A, Errigo A et al.. Three sisters with very-late-onset major depression and parkinsonism.  Parkinsonism Relat Disord. 2006; May 29;  , (Epub ahead of print)
    PubMedGoogle Scholar
  • 29 Hung I H, Suzuki M, Yamaguchi Y, Yuan D S, Klausner R D, Gitlin J D. Biochemical characterization of the Wilson disease protein and functional expression in the yeast Saccharomyces cerevisiae .  J Biol Chem. 1997;  272 21461-21466
    CrossrefPubMedGoogle Scholar
  • 30 La Fontaine S, Theophilos M B, Firth S D, Gould R, Parton R G, Mercer J F. Effect of the toxic milk mutation (tx) on the function and intracellular localization of Wnd, the murine homologue of the Wilson copper ATPase.  Hum Mol Genet. 2001;  10 361-370
    CrossrefPubMedGoogle Scholar
  • 31 Forbes J R, Cox D W. Copper-dependent trafficking of Wilson disease mutant ATP7B proteins.  Hum Mol Genet. 2000;  9 1927-1935
    CrossrefPubMedGoogle Scholar
  • 32 Mufti A R, Burstein E, Csomos R A et al.. XIAP is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders.  Mol Cell. 2006;  21 775-785
    CrossrefPubMedGoogle Scholar
  • 33 Gibbs K, Walshe M. A study of the ceruloplasmin concentrations found in 75 patients with Wilson's disease, their kinships and various control groups.  Q J Med. 1979;  48 447-463
    PubMedGoogle Scholar
  • 34 Walshe J M. Wilson's disease: the presenting symptoms.  Arch Dis Child. 1962;  37 253-256
    PubMedGoogle Scholar
  • 35 Walshe J M. Wilson's disease (HLD). In: Vinken PJ, Bruyn GW Handbook of Clinical Neurology. Vol. 27. Amsterdam; North Holland Publishing Company 1976: 379-414
    Google Scholar
  • 36 Beyersdorff A, Findeisen A. Morbus Wilson: case report of a two-year-old child as first manifestation.  Scand J Gastroenterol. 2006;  41 496-497
    CrossrefPubMedGoogle Scholar
  • 37 Gow P J, Smallwood R A, Angus P W, Smith A L, Wall A J, Sewell R B. Diagnosis of Wilson's disease: an experience over three decades.  Gut. 2000;  46 415-419
    CrossrefPubMedGoogle Scholar
  • 38 Sternlieb I, Scheinberg I H. Chronic hepatitis as a first manifestation of Wilson's disease.  Ann Intern Med. 1972;  76 59-64
    PubMedGoogle Scholar
  • 39 Scott J, Gollan J L, Samourian S, Sherlock S. Wilson's disease presenting as chronic active hepatitis.  Gastroenterology. 1978;  74 645-651
    PubMedGoogle Scholar
  • 40 Schilsky M L, Fink S. Inherited metabolic liver disease.  Curr Opin Gastroenterol. 2006;  22 215-222
    PubMedGoogle Scholar
  • 41 Schilsky M L, Scheinberg I H, Sternlieb I. Liver transplantation for Wilson's disease: indications and outcome.  Hepatology. 1994;  19 583-587
    PubMedGoogle Scholar
  • 42 Roche-Sicot J, Benhamou J P. Acute intravascular hemolysis and acute liver failure associated as a first manifestation of Wilson's disease.  Ann Intern Med. 1977;  86 301-303
    PubMedGoogle Scholar
  • 43 Strickland G T, Leu M L. Wilson's disease: clinical and laboratory manifestations in 40 patients.  Medicine. 1975;  54 113-137
    PubMedGoogle Scholar
  • 44 Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis.  Hepatology. 2005;  41 668-670
    CrossrefPubMedGoogle Scholar
  • 45 Hellman N E, Gitlin J D. Ceruloplasmin metabolism and function.  Annu Rev Nutr. 2002;  22 439-458
    CrossrefPubMedGoogle Scholar
  • 46 Parker N. Hereditary whispering dysphonia.  J Neurol Neurosurg Psychiatry. 1985;  48 218-224
    PubMedGoogle Scholar
  • 47 Cartwright G E. Diagnosis of treatable Wilson's disease.  N Engl J Med. 1978;  298 1347-1350
    PubMedGoogle Scholar
  • 48 Walshe J M, Yealland M. Wilson's disease: the problem of delayed diagnosis.  J Neurol Neurosurg Psychiatry. 1992;  55 692-696
    PubMedGoogle Scholar
  • 49 Svetel M, Kozic D, Stefanova E, Semnic R, Dragasevic N, Kostic V S. Dystonia in Wilson's disease.  Mov Disord. 2001;  16 719-723
    CrossrefPubMedGoogle Scholar
  • 50 Barbosa E R, Silveira-Moriyama L, Machado A C, Bacheschi L A, Rosemberg S, Scaff M. Wilson's disease with myoclonus and white matter lesions.  Parkinsonism Relat Disord. 2006; May 30;  (Epub ahead of print) 
    PubMedGoogle Scholar
  • 51 Papapetropoulos S, Singer C. Painless legs moving toes in a patient with Wilson's disease.  Mov Disord. 2006;  21 579-580
    CrossrefPubMedGoogle Scholar
  • 52 Bhattacharya K, Velickovic M, Schilsky M, Kaufmann H. Autonomic cardiovascular reflexes in Wilson's disease.  Clin Auton Res. 2002;  12 190-192
    CrossrefPubMedGoogle Scholar
  • 53 Meenakshi-Sundaram S, Taly A B, Kamath V, Arunodaya G R, Rao S, Swamy H S. Autonomic dysfunction in Wilson's disease: a clinical and electrophysiological study.  Clin Auton Res. 2002;  12 185-189
    CrossrefPubMedGoogle Scholar
  • 54 Dening T R, Berrios G E, Walshe J M. Wilson's disease and epilepsy.  Brain. 1988;  111 1139-1155
    CrossrefPubMedGoogle Scholar
  • 55 Polychronopoulos P, Argyriou A A, Papapetropoulos S, Gourzis P, Rigas G, Chroni E. Wilson's disease and benign epilepsy of childhood with centrotemporal (rolandic) spikes.  Epilepsy Behav. 2006;  8 438-441
    CrossrefPubMedGoogle Scholar
  • 56 Kumar S. Wilson's disease presenting as status epilepticus.  Indian Pediatr. 2005;  42 492-493
    PubMedGoogle Scholar
  • 57 Jung K H, Ahn T B, Jeon B S. Wilson disease with an initial manifestation of polyneuropathy.  Arch Neurol. 2005;  62 1628-1631
    CrossrefPubMedGoogle Scholar
  • 58 Mueller A, Reuner U, Landis B, Kitzler H, Reichmann H, Hummel T. Extrapyramidal symptoms in Wilson's disease are associated with olfactory dysfunction.  Mov Disord. 2006;  21 1311-1316
    CrossrefPubMedGoogle Scholar
  • 59 Akil M, Schwartz J A, Dutchak D, Yuzbasiyan-Gurkan V, Brewer G J. The psychiatric presentations of Wilson's disease.  J Neuropsychiatry Clin Neurosci. 1991;  3 377-382
    PubMedGoogle Scholar
  • 60 Brewer G J. Behavioral abnormalities in Wilson's disease.  Adv Neurol. 2005;  96 262-274
    PubMedGoogle Scholar
  • 61 Oder W, Grimm G, Kollegger H, Ferenci P, Schneider B, Deecke L. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases.  J Neurol. 1991;  238 281-287
    PubMedGoogle Scholar
  • 62 Dening T R. Psychiatric aspects of Wilson's disease.  Br J Psychiatry. 1985;  147 677-682
    PubMedGoogle Scholar
  • 63 Kaul A, McMahon D. Wilson's disease and offending behavior: a case report.  Med Sci Law. 1993;  33 353-358
    PubMedGoogle Scholar
  • 64 Seniow J, Bak T, Gajda J, Poniatowska R, Czlonkowska A. Cognitive functioning in neurologically symptomatic and asymptomatic forms of Wilson's disease.  Mov Disord. 2002;  17 1077-1083
    CrossrefPubMedGoogle Scholar
  • 65 Portala K, Levander S, Westermark K, Ekselius L, von Knorring L. Pattern of neuropsychological deficits in patients with treated Wilson's disease.  Eur Arch Psychiatry Clin Neurosci. 2001;  251 262-268
    CrossrefPubMedGoogle Scholar
  • 66 Gronlund J, Nanto-Salonen K, Venetoklis J, Holmberg R L, Heinonen A, Stahlberg M R. Poor cognitive development and abdominal pain: Wilson's disease.  Scand J Gastroenterol. 2006;  41 361-364
    CrossrefPubMedGoogle Scholar
  • 67 Brewer G J. Recognition, diagnosis, and management of Wilson's disease.  Proc Soc Exp Biol Med. 2000;  223 39-46
    PubMedGoogle Scholar
  • 68 Wiebers D O, Hollenhorst R W, Goldstein N P. The ophthalmologic manifestations of Wilson's disease.  Mayo Clin Proc. 1977;  52 409-416
    PubMedGoogle Scholar
  • 69 Johnson R E, Campbell R J. Wilson's disease: electron microscopic, x-ray energy spectroscopic, and atomic absorption spectroscopic studies of corneal copper deposition and distribution.  Lab Invest. 1982;  46 564-569
    PubMedGoogle Scholar
  • 70 Innes J R, Strachan I M, Triger D R. Unilateral Kayser-Fleischer ring.  Br J Ophthalmol. 1986;  70 469-470
    PubMedGoogle Scholar
  • 71 Sussman W, Scheinberg I H. Disappearance of Kayser-Fleischer rings: effects of penicillamine.  Arch Ophthalmol. 1969;  82 738-741
    PubMedGoogle Scholar
  • 72 Ross M E, Jacobson I M, Dienstag D L, Martin J B. Late onset Wilson's disease with neurological involvement in the absence of Kayser-Fleischer rings.  Ann Neurol. 1985;  17 411-413
    CrossrefPubMedGoogle Scholar
  • 73 Pfeiffer R F. Wilson's disease. In: Watts RL, Koller WC Movement Disorders. Neurologic Principles and Practice. New York; McGraw-Hill Medical Publishers 2004: 779-797
    Google Scholar
  • 74 Siemerling E, Oloff H. Pseudosklerose (Westphal-Strümpell) mit Cornealring (Kayser-Fleischer) und doppelseitiger Scheinkatarakt, die nur bei seitlicher Beleuchtnung sichtbar ist und die der nach Verletzung durch Kupfersplitter entstehenden Katarakt änlich ist.  Klin Wochenschr. 1922;  1 1087-1089
    CrossrefPubMedGoogle Scholar
  • 75 Cairns J E, Williams H P, Walshe J M. “Sunflower cataract” in Wilson's disease.  Br Med J. 1969;  3 95-96
    PubMedGoogle Scholar
  • 76 Golding D N, Walshe J M. Arthropathy of Wilson's disease: study of clinical and radiological features in 32 patients.  Ann Rheum Dis. 1977;  36 99-111
    PubMedGoogle Scholar
  • 77 Canelas H M, Carvalho N, Scaff M, Vitule A, Barbosa E R, Azevedo E M. Osteoarthropathy of hepatolenticular degeneration.  Acta Neurol Scand. 1978;  57 481-487
    PubMedGoogle Scholar
  • 78 Mindelzun R, Elkin M, Scheinberg I H, Sternlieb I. Skeletal changes in Wilson's disease: a radiological study.  Radiology. 1970;  94 127-132
    PubMedGoogle Scholar
  • 79 Yarze J C, Martin P, Munoz S J, Friedman L S. Wilson's disease: current status.  Am J Med. 1992;  92 643-654
    CrossrefPubMedGoogle Scholar
  • 80 McIntyre N, Clink H M, Levi A J, Cumings J N, Sherlock S. Hemolytic anemia in Wilson's disease.  N Engl J Med. 1967;  276 439-444
    PubMedGoogle Scholar
  • 81 Sternlieb I. Wilson's disease: indications for liver transplants.  Hepatology. 1984;  4 15S-17S
    PubMedGoogle Scholar
  • 82 Donfrid M, Jankovic G, Strahinja R, Colovic R, Begic-Janeva A, Colovic M. Idiopathic thrombocytopenia associated with Wilson's disease.  Hepatogastroenterology. 1998;  45 1774-1776
    PubMedGoogle Scholar
  • 83 Atanassova P A, Panchovska M S, Tzvetanov P, Chalakova N T, Masaldzhieva R I, Dimitrov B D. Hepatolenticular degeneration combined with primary antiphospholipid syndrome: a case report.  Eur Neurol. 2006;  55 42-43
    CrossrefPubMedGoogle Scholar
  • 84 Wiebers D O, Wilson D M, McLeod R A, Goldstein N P. Renal stones in Wilson's disease.  Am J Med. 1979;  67 249-254
    CrossrefPubMedGoogle Scholar
  • 85 Narayanan P, Chetan G, Mahadevan S. Wilson's disease presenting as respiratory failure.  Indian J Pediatr. 2006;  73 99-100
    PubMedGoogle Scholar
  • 86 Leu M L, Strickland G T, Wang C C, Chen T S. Skin pigmentation in Wilson's disease.  JAMA. 1970;  211 1542-1543
    CrossrefPubMedGoogle Scholar
  • 87 Scheinberg I H, Sternlieb I. Wilson's disease.  Annu Rev Med. 1965;  16 119-134
    CrossrefPubMedGoogle Scholar
  • 88 Lau J Y, Lai C L, Wu P C, Pan H Y, Lin H J, Todd D. Wilson's disease: 35 years' experience.  Q J Med. 1990;  75 597-605
    PubMedGoogle Scholar
  • 89 Ferenci P, Steindl-Munda P, Vogel W et al.. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's disease.  Clin Gastroenterol Hepatol. 2005;  3 811-818
    CrossrefPubMedGoogle Scholar
  • 90 Smallwood R A, Williams H A, Rosenoer V M, Sherlock S. Liver-copper levels in liver disease: studies using neutron activation analysis.  Lancet. 1968;  2 1310-1313
    PubMedGoogle Scholar
  • 91 Benson G D. Hepatic copper accumulation in primary biliary cirrhosis.  Yale J Biol Med. 1979;  52 83-88
    PubMedGoogle Scholar
  • 92 Willeit J, Kiechl S G. Wilson's disease with neurologic impairment but no Kayser-Fleischer rings.  Lancet. 1991;  337 1426
    PubMedGoogle Scholar
  • 93 Oracz G, Klimczak-Slaczka D, Sokolowska-Oracz A et al.. [Prevalence of Kayser-Fleischer ring in patients with Wilson's disease]. [In Polish].  Klin Oczna. 2005;  107 54-56
    PubMedGoogle Scholar
  • 94 Das S K, Ray K. Wilson's disease: an update.  Nat Clin Pract Neurol. 2006;  2 482-493
    CrossrefPubMedGoogle Scholar
  • 95 Sinha S, Taly A B, Ravishankar S et al.. Wilson's disease: cranial MRI observations and clinical correlation.  Neuroradiology. 2006;  48 613-621
    CrossrefPubMedGoogle Scholar
  • 96 Walter U, Krolikowski K, Tarnacka B, Benecke R, Czlonkowska A, Dressler D. Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease.  Neurology. 2005;  64 1726-1732
    CrossrefPubMedGoogle Scholar
  • 97 Hartard C, Weisner B, Dieu C, Kunze K. Wilson's disease with cerebral manifestation: monitoring therapy by CSF copper concentration.  J Neurol. 1993;  241 101-107
    PubMedGoogle Scholar
  • 98 Hoogenraad T U. Paradigm shift in the treatment of Wilson's disease: zinc therapy now treatment of choice.  Brain Dev. 2006;  28 141-146
    CrossrefPubMedGoogle Scholar
  • 99 Walshe J M. Penicillamine, a new oral therapy for Wilson's disease.  Am J Med. 1956;  21 487-495
    CrossrefPubMedGoogle Scholar
  • 100 Brewer G J, Askari F, Lorincz M T et al.. Treatment of Wilson disease with ammonium tetrathiomolybdate.  Arch Neurol. 2006;  63 521-527
    CrossrefPubMedGoogle Scholar
  • 101 Walshe J M, Yealland M. Chelation treatment of neurological Wilson's disease.  Q J Med. 1993;  86 197-204
    PubMedGoogle Scholar
  • 102 Brewer G J, Terry C A, Aisen A M, Hill G M. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy.  Arch Neurol. 1987;  44 490-493
    CrossrefPubMedGoogle Scholar
  • 103 Prashanth L K, Taly A B, Sinha S et al.. Prognostic factors in patients presenting with severe neurological forms of Wilson's disease.  QJM. 2005;  98 557-563
    CrossrefPubMedGoogle Scholar
  • 104 Sternlieb I, Scheinberg I H. Penicillamine therapy for hepatolenticular degeneration.  JAMA. 1964;  189 748-754
    PubMedGoogle Scholar
  • 105 Haggstrom G D, Hirschowitz B I, Flint A. Long-term penicillamine therapy for Wilson's disease.  South Med J. 1980;  73 530-531
    PubMedGoogle Scholar
  • 106 Sternlieb I, Fisher M, Scheinberg I H. Penicillamine-induced skin lesions.  J Rheumatol Suppl. 1981;  7 149-154
    PubMedGoogle Scholar
  • 107 Walshe J M. Penicillamine: the treatment of first choice for patients with Wilson's disease.  Mov Disord. 1999;  14 545-550
    CrossrefPubMedGoogle Scholar
  • 108 Schafer D F, Shaw Jr B W. Fulminant hepatic failure and orthotopic liver transplantation.  Semin Liver Dis. 1989;  9 189-194
    PubMedGoogle Scholar
  • 109 Medici V, Mirante V G, Fassati L R et al.. Liver transplantation for Wilson's disease: the burden of neurological and psychiatric disorders.  Liver Transpl. 2005;  11 1056-1063
    CrossrefPubMedGoogle Scholar
  • 110 Wang X H, Cheng F, Zhang F et al.. Living-related liver transplantation for Wilson's disease.  Transpl Int. 2005;  18 651-656
    CrossrefPubMedGoogle Scholar
  • 111 Tamura S, Sugawara Y, Kishi Y, Akamatsu N, Kaneko J, Makuuchi M. Living-related liver transplantation for Wilson's disease.  Clin Transplant. 2005;  19 483-486
    CrossrefPubMedGoogle Scholar

Ronald F PfeifferM.D. 

Professor and Vice Chair, Department of Neurology, University of Tennessee Health Science Center

855 Monroe Avenue, Memphis, TN 38163

      >